Btomorrow Ventures (BTV), the corporate venture capital arm of BAT, has invested an undisclosed amount in Kanvas Co., a developer of patented electronic evaporator technology solutions.
This investment will facilitate the research, development, and growth required to commercialize Kanvas' proprietary Vapetelligence technology platform, and further enable the scalability of their products designed to promote device safety in the global electronic vaporizer and regulated market.
Kanvas CEO Andy Fathollahi stated in a press release that the company is pleased to partner with BTV as strategic investors in order to commercialize their unique IP portfolio and technology platform. They will focus on their patented temperature control and dosing technology and hardware to provide secure and controlled delivery systems for brands.
Kanvas' innovative approach will serve as a catalyst for brands to integrate higher quality software and intelligent chip technology, enabling better and safer consumer experiences.
BTV is delighted to support Kanvas. With its innovative product proposal, strong management team, and strategic partnership with BAT, we believe the company is ready to succeed. We welcome Kanvas to BTV's investment portfolio," said BTV Investment Director Lukasz Garbowski.
Kanvas possesses a diverse portfolio of patents in technology, software, and hardware products, offering a comprehensive set of high-quality solutions for brands in the electronic delivery of CBD, cannabis, and nicotine.
Statement
This article has been compiled from third-party information and is intended only for industry professionals to exchange and learn from.
This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content of the article. The compilation of this article is only intended for industry exchange and research.
Due to limitations in translation abilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.
2FIRSTS is completely aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.
The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
